A carregar...
The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?
Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer. Bevacizumab has demonstrated a gain in progression-free survival and a trend towards an overall survival benefit in v...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing AG
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3661078/ https://ncbi.nlm.nih.gov/pubmed/23710429 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2193-1801-2-202 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|